Senores Pharmaceuticals Limited has informed the Exchange regarding Appointment of Senior Management Personnel of the Company
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Senores Pharmaceuticals has informed the stock exchanges of two changes in its Senior Management Personnel (SMP), both effective March 17, 2026. First, Mr. Jatin Gajjar, the company's existing Chief Technology Officer, has been officially categorized as an SMP following a board resolution recommended by the Nomination and Remuneration Committee. Mr. Gajjar brings over 30 years of pharma experience, with prior leadership roles at Amneal, Sun Pharma, Alembic, Zydus Cadila, Torrent Pharma, and Aventis Pharma. Second, Mr. Manohar Lalge, President – Research and Development, has resigned and will cease to be an SMP from the close of business on the same day. The company has disclosed the details in an annexure as required by SEBI LODR regulations.
The simultaneous exit of the R&D head and formalization of the CTO's SMP status may create a short-term leadership gap in research operations, but the CTO's deep experience in complex generics and injectable formulations could help ensure continuity. Investors should watch for any further disclosures on R&D strategy or replacement plans.